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Host genetic variability may contribute to susceptibility of bacterial meningitis, but which genes 
contribute to the susceptibility to this complex disease remains undefined. We performed a genetic 
association study in 469 community-acquired pneumococcal meningitis cases and 2072 population-
based controls from the Utrecht Health Project in order to find genetic variants associated with 
pneumococcal meningitis susceptibility. A HumanExome BeadChip was used to genotype 102,097 
SNPs in the collected DNA samples. Associations were tested with the Fisher exact test. None of the 
genetic variants tested reached Bonferroni corrected significance (p-value <5 × 10−7). Our strongest 
signals associated with susceptibility to pneumococcal meningitis were rs139064549 on chromosome 
1 in the COL11A1 gene (p = 1.51 × 10−6; G allele OR 3.21 [95% CI 2.05–5.02]) and rs9309464 in 
the EXOC6B gene on chromosome 2 (p = 6.01 × 10−5; G allele OR 0.66 [95% CI 0.54–0.81]). The 
sequence kernel association test (SKAT) tests for associations between multiple variants in a gene 
region and pneumococcal meningitis susceptibility yielded one significant associated gene namely 
COL11A1 (p = 1.03 × 10−7). Replication studies are needed to validate these results. If replicated, the 
functionality of these genetic variations should be further studied to identify by which means they 
influence the pathophysiology of pneumococcal meningitis.
Acute bacterial meningitis is a life-threatening disease associated with substantial morbidity and mortality and 
ranks among the top 10 infectious causes of death1,2. Streptococcus pneumoniae is the leading causative pathogen 
and is identified in 70% of adult patients3,4. Despite early antibiotic and anti-inflammatory therapy, case fatality 
rates of pneumococcal meningitis range from 18–30%, and neurological sequelae, including hearing loss, focal 
neurological deficits, and cognitive impairment, occur in 30–55% of surviving patients4–10.
Several factors have been identified that contribute to the susceptibility to pneumococcal meningitis11. For 
example, patients with an immunocompromised state, organ transplantation, splenectomy or anatomical defects 
with cerebrospinal fluid leakage are at increased risk of pneumococcal meningitis12–15. Genetic variation leading 
to difference in immune response has also been identified to influence susceptibility to pneumococcal menin-
gitis. Extreme phenotype studies looking at recurrent pneumococcal disease have shown that genetic variation 
in complement factor 2 (C2), interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor κ B essential 
modulator protein (NEMO) were the cause of this increased susceptibility16. Furthermore, case-control studies 
mostly looking at variants in genes involved in the innate immune system have pointed out genetic variants 
associated with acquiring invasive pneumococcal disease16–20. In a Dutch case-control study genetic variations in 
the beta2-adrenoreceptor (ADRB2) and mannose binding lectin (MBL) genes were associated with susceptibility 
to pneumococcal meningitis17,18. These genetic association studies evaluated one or only few single-nucleotide 
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polymorphisms within one gene in relatively small cohorts. A hypothesis-free approach in larger groups of 
patients and controls is needed to unravel new genetic risk factors for the susceptibility to pneumococcal men-
ingitis. The aim of our study was to identify new genetic variants involved in susceptibility to pneumococcal 
meningitis, genotyping over 240,000 genetic variants of which the majority is exonic or otherwise functional.
Results
Between 2006 and 2011, 656 patients with bacterial meningitis were included in the MeninGene study21. Of these 
patients, 469 (72%) had pneumococcal meningitis. After quality control filters 408 pneumococcal meningitis 
patients and 2072 controls were included in the genetic associations analysis for meningitis disease susceptibility. 
Demographic and clinical data of the successfully genotyped patients can be found in Table 1. After exclusion of 
all monomorf and sex chromosome variants a total of 100,464 single nucleotide polymorphisms (SNPs) passed 
quality control thresholds of > 95% call rate and Hardy Weinberg equilibrium and were incorporated in the asso-
ciation analysis.
The genomic control parameter λ was 0.31 when all variations were included. This was driven by the rare vari-
ants and exclusion of variants with a minor allele frequency below 0.01%, increased λ to 0.93 (Supplementary Fig. 1). 
For our single marker analysis we therefore included those with a minor allele frequency higher than 0.01%.
None of the tested genetic variants reached the Bonferroni corrected significance threshold (p-value < 
5 × 10−7). Six genetic variants associated with pneumococcal meningitis reached p-values lower than 1 × 10−4 
(Fig. 1). Our strongest signal was the missense rs139064549 in the collagen type XI alpha 1 (COL11A1) gene 
(p = 1.51 × 10−6; G allele OR 3.21 [95% CI 2.05–5.02]) and the second strongest was the intron variant rs9309464 
in the exocyst complex component 6B (EXOC6B) gene (p = 6.01 × 10−5; G allele OR 0.66 [95% CI 0.54–0.81]; 
Table 2). Of these six variants with a p-value lower than 1 × 10−4, three variants were located in the fibrous sheath 
CABYR binding protein (FSCB) gene, namely rs3809429 (p = 6.80 × 10−5; A-allele OR 1.65 [95% CI 1.30–2.09]), 
rs3825630 (p = 6.80 × 10−5; G allele OR 1.65 [95% CI 1.30–2.09]), and rs1959379 (p = 8.81 × 10−5; A allele OR 
1.64 [95% CI 1.30–2.09]). The sixth variant rs617169 (p = 7.33 × 10−5; G allele OR 0.72 [95% CI 0.61–0.85]) was 
not located within a gene, but the nearest gene was protein kinase N2 (PKN2) located on chromosome 2.
In the single marker analysis we did not include variants with a MAF below 0.01%. To assess the role of 
these rare variants in the association testing of pneumococcal susceptibility we used the region based sequence 
kernel association test (SKAT) allowing us to include all common and rare variations within a gene region. By 
using the SKAT analysis, we found one significant associated gene namely COL11A1 (p = 1.03 × 10−7). In this 
analysis we tested a total of 12968 gene sets and after correcting for these multiple tests COL11A1 reaches a 
significance of p = 0.001. No difference in the p-value of COL11A1 was observed when correcting for the pro-
portion of case-control imbalance. The second strongest signal in the SKAT analysis was the polymerase (DNA 
directed) lambda (POLL) gene (p = 8.10 × 10−5), which was not significant after multiple testing correction. 
When corrected this p-value for proportion of case-control imbalance the association was slightly more signif-
icant (p = 7.05 × 10−5). We also looked if the portion of common and rare variants drove the associations with 
pneumococcal meningitis susceptibility when the rare variants threshold was defined as a function of the total 
sample size22. This analysis showed only for POLL (p = 1.90 × 10−5) that association was based on the proportion 
of common and rare variants, although this did not reach genome-wide significance after correction for multiple 
testing.
Characteristics
Pneumococcal meningitis 
patients (n = 408)
Number of male cases (%) 190/408 (47%)
Mean age, years (SD) 59 yrs. (14)
Symptoms before admission:
 Seizures (%) 29/389 (8%)
 Duration of symptoms < 24 hours (%) 199/391 (51%)
Predisposing conditions
 Sinusitis/otitis media (%) 189/401 (47%)
 Pneumonia (%) 40/390 (10%)
 Immunocompromised state (%) 103/402 (26%)
Clinical characteristics on admission
 Classic triad (%) 208/391 (53%)
 Coma (%) 57/402 (14%)
Laboratory characteristics on admission
 Median CSF leukocyte count (IQR) 4500 cells/3mm3 (941–10856)
 Median CRP (IQR) 194 mg/L (83–306)
 Mean thrombocyte count (SD) 218 × 10^9/L (86)
 Unfavorable outcome (%) 135/402 (34%)
 Death (%) 31/402 (8%)
Table 1.  Demographic and clinical data of the included pneumococcal meningitis patients.
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Discussion
We performed the first hypothesis free exome-wide association study on disease susceptibility in a large homo-
geneous group of pneumococcal meningitis patients. We did not identify a significant association in our single 
marker analysis after correction for multiple testing. The strongest associations of single nucleotide variations 
with pneumococcal meningitis susceptibility are found within genes that have not been related to pneumococcal 
meningitis or pneumococcal disease previously. Our strongest signal (rs139064549) is located in the COL11A1 
gene, which encodes for one component of type XI collagen that adds structure and strength to connective tissues. 
COL11A1 has a fundamental role in the control of fibrillogenesis and mutations in this gene are associated with 
Stickler syndrome23,24. Stickler syndrome is a genetic disorders affecting connective tissue and is characterized 
by distinctive facial abnormalities, ocular problems, hearing loss and joint problems24. Related gene ontologies of 
the COL11A1 gene are extracellular matrix structural constituents and extracellular binding. The association of 
the COL11A1 gene could indicate that differences in the extracellular matrix or anatomical defects can alter the 
susceptibility of pneumococcal meningitis. The second strongest association (rs9309464) is located in an intronic 
region of the EXOC6B gene. The EXOC6B gene is part of a multiprotein complex required for targeted exocytosis. 
This complex is highly expressed in the central nervous system and is important for cell polarity, growth and 
neuronal cell migration25. In previous studies, genetic variations affecting the EXOC6B gene have been associ-
ated with cerebral disorders, like intellectual disability, but associations with infectious diseases have not been 
reported26. The three genetic associations found in the FSCB gene are all intron variants. FSCB is a testis specific 
protein and in mice it is suggested be involved in the later stages of fibrous sheath assembly of spermiogenesis27. 
The FSCB gene is not described to be associated with neurological or infectious diseases in earlier studies. Since 
rs617169, the fifth strongest associated variant is located outside any gene and therefore we could not explain the 
possible involvement during pneumococcal meningitis susceptibility. The closest gene to rs617169 is the PKN2 
gene encoding for a multifunctional protein kinase N228.
The SKAT analysis, performed to identify differences between patients and controls in the prevalence of a set 
of variants within genes, showed the association of one gene; COL11A1. As expected, most rare variants were 
found in the largest group, namely the control group. This finding suggests that the fivefold difference in amount 
of patients and controls is responsible for the significant differences we have found. We tried to determine this 
effect by applying the hybrid SKAT resampling method to test the proportion of case-control imbalance. This did 
not result in a noteworthy change of the p-value. Consequently, this indicates that a larger number of patients is 
needed to determine the true role of rare variants in pneumococcal meningitis susceptibility. As described above, 
we found a marginally significant association of the COL11A1 gene with pneumococcal meningitis susceptibility. 
The second highest association is found in the POLL gene and was not significance after correction for multiple 
Figure 1. Manhattan plot of p-values . The y-axis indicates the –log10 (p-values) of the SNPs in the association 
analysis and the x-axis indicates the chromosomal position. The horizontal blue line indicates the threshold of 
p = 1 × 10−4. All markers of the three genes with the highest association signal, namely COL11A1 (rs139064549, 
p-value = 1.51 × 10−6, location chromosome 1) , EXOC6B (rs9309464, p-value = 6.01 × 10−5, location chromosome 
2) and FSCB (with rs3809429, rs3825630 rs1959379, p-value = 6.80 × 10−5, 6.80 × 10−5, 8.81 × 10−5 location 
chromosome 14), have been colored green.
Chr Basepair Rs number Gene
Alleles A1 allele frequency P-value
OR (+/− 95 CI)A1 A2 Cases Control Unadjusted BONF
1 103354135 rs139064549 COL11A1 G C 0.0393 0.0126 1.51 × 10−6 0.15 3.21 (2.05–5.02)
2 72533963 rs9309464 EXOC6B G A 0.146 0.206 6.01 × 10−5 1 0.66 (0.54–0.81)
14 44975606 rs3809429 FSCB G A 0.123 0.0784 6.80 × 10−5 1 1.65 (1.30–2.09)
14 44975052 rs3825630 FSCB A C 0.123 0.784 6.80 × 10−5 1 1.65 (1.30–2.09)
1 88745673 rs617169 – G A 0.281 0.353 7.33 × 10−5 1 0.72 (0.61–0.85)
14 44974966 rs1959379 FSCB A G 0.123 0.0785 8.81 × 10−5 1 1.64 (1.30–2.09)
Table 2.  Susceptibility to pneumococcal meningitis (6 lowest P-values/Fisher exact test).
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testing. POLL encodes for a DNA polymerase, which participates in V(D)J recombination to generate B-cell and 
T-cell receptor diversity. In animal models POLL seems to be important for light-chain rearrangements29. The 
potential role of POLL in B-cell and T-cell differentiation could explain that genetic variation in this gene influ-
ences pneumococcal meningitis susceptibility.
Previous genetic association studies in pneumococcal meningitis susceptibility have used a hypothesis driven 
approach in relatively small cohorts16–20,30. For example, association of a set of polymorphisms in the MBL2 gene 
resulted in a p-value of 0.017 (OR 8.21 [95% CI 1.05–64.09]) and the highest association of a SNP in the ADRB2 
gene had a p-value of 0.007 (OR 1.52 [95% CI 1.12–2.07]) were reported. In our data the set of SNPs in MBL2 
gene reached a p-value of 0.09 (OR 1.65 [95% CI 0.91–2.98]) and the same genetic variation in the ADRB2 gene 
a p-value of 0.164 (OR 1.12 [95% CI 0.1–1.3]). The associations found in those studies were not very strong and 
both studies concluded validation in larger populations is needed17,18. The challenge in genetic association studies 
looking at infectious diseases is the reproducibility of the data. The strength of our unique pneumococcal men-
ingitis patient cohort is the homogenous group of patients but we are limited in replication of our findings in a 
similar group of patients. Especially since we found one gene with exome wide significance, replication of this 
association within another patient population is essential to validate this result.
Another limitation of our study is that by using the exome SNP array, it remains unclear if the associated 
genetic variants are also the causal variants with a biological function. Potentially the identified variants are in 
linkage disequilibrium -pair wise correlation between nearby genetic variants- with the causal variants.
We observed minimal deviation from the null for variants with MAF > 0.2 with a p-value < 0.01 (see sup-
plement Fig. 1A). Permutation-based approach did increase lambda to 1.02, but did not affect the early devia-
tion from the null. Likely causes of the early deviation are the technical (genotyping) and population differences 
between the cases and controls, or missing covariates such as antibiotic use or occurrence of co-infections (sup-
plement Fig. 1C).
Our current study did not detect previously reported associations. This could be explained by our homog-
enous category of pneumococcal meningitis patients. Susceptibility to invasive pneumococcal infections is 
strongly dependent on host-pathogen interaction, therefore specifying the causing pathogen and type of infection 
can be crucial in determining specific risk genes for a complex trait like pneumococcal meningitis.
Conclusion
Our study reveals new genetic variants associated with the susceptibility to pneumococcal meningitis. These 
genetic variations were just below exome-wide significance. We found one gene significantly associated when 
looking for associations between multiple common and rare variants with pneumococcal meningitis susceptibil-
ity, namely the COL11A1 gene. These findings need to be replicated in an independent pneumococcal meningitis 
patient cohort. Following replication studies, the role of these genes in the pathogenesis of pneumococcal men-
ingitis needs to be determined. Increasing our biological insight into the pathogenesis of bacterial meningitis 
brings us one step closer to understanding the disease, and discovering new therapeutic and preventive strategies.
Methods
Study cohort and data collection. Patients included in this study are part of a prospective nationwide 
observational cohort study in the Netherlands; the MeninGene study4. For this study, all patients of 16 years and 
older with a community acquired bacterial meningitis were included from 2006 to 2011. Bacterial meningitis 
was defined by positive culture of a bacterial pathogen in the cerebrospinal fluid or a positive polymerase chain 
reaction test for a bacterial pathogen in the cerebrospinal fluid in combination with specific cerebrospinal fluid 
findings indicative of bacterial meningitis31. The Netherlands Reference Laboratories for Bacterial Meningitis 
(NRLBM) provided researchers of the MeninGene study with a daily update of where patients with bacterial 
meningitis have been admitted in the preceding days. Furthermore, physicians could contact the researchers to 
include patients with a 24/7 telephone service. Patients with hospital acquired bacterial meningitis, severe head 
trauma or neurosurgery in the previous month, or with a neurosurgical device in the central nervous system were 
excluded. Online case-record forms were used to collect data on patients’ history, symptoms and laboratory find-
ings during admission, treatment, clinical course during hospitalized period and outcome at discharge.
Blood for DNA extraction was drawn from the patients and collected in sodium/EDTA tubes. Isolation of 
the DNA was performed with the Gentra Puregene isolation kit (Qiagen) according to manufacturer’s proto-
col. Thereafter the yield and quality of the extractions were determined to ensure appropriate conditions for 
genotyping.
The control population comprised 2072 individuals from the Utrecht Health project32. The Utrecht Health 
Project (UHP) is an ongoing dynamic population study initiated in a newly developed large residential area in 
Leidsche Rijn, part of the city of Utrecht. All new inhabitants were invited by their general practitioner to partici-
pate in the UHP. Of all participants an individual health profile (IHP) was made by dedicated research nurses. In 
a sample of the UHP participants genomic data has been collected.
Genotyping and quality control. All bacterial meningitis patients and controls were genotyped using 
the Illumina Exome array v1.1 in collaboration with the Human Genome Facility and the department of 
Epidemiology, Erasmus MC, the Netherlands as part of the Netherlands ExomeChip Project. After genotyp-
ing we performed calling on our MeninGene samples and to improve calling accuracy samples were joined 
with UHP and other Utrecht BBMRI-NL cohorts comprising N = 9844 samples. The samples from the other 
Utrecht BBMRI-NL cohorts were excluded after quality control (QC). All autosomal SNPs were called using 
GenomeStudio software, from Illumina, using the GenTrain 2.0 cluster algorithm using the protocol as described 
in Guo et al.33.
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Called data was exported in PLINK format for final sample and SNP QC34. High quality, independent SNPs 
with less than 1% missing values, no significant differences in missing values between cases and controls, minor 
allele frequency (MAF) > 5% and Hardy-Weinberg equilibrium (HWE) > 1 × 10−3 were used to determine relat-
edness, heterozygostiy and ancestry. Individuals with a minimal second degree of relatedness, or higher degree 
relatedness and heterozygosity above or below three standard deviations were left out. To avoid population 
stratification we used multidimensional scaling (MDS), implemented in PLINK, on all meningitis cases, con-
trols and HapMap samples to select only those patients that clustered with the European CEU HapMap samples 
(Supplementary Fig. 2)35. Finally we performed QC by removing all SNPs that had > 5% missing values and HWE 
p-value < 1 × 10−6.
Statistical analyses. Differences between cases and controls were calculated using the Fisher’s exact test 
on allelic association using PLINK 1.936. To correct for multiple testing we applied the Bonferroni correction 
(P < 0.05/number of analyzed SNPs). To investigate if permutation-adjustment removed the inflation permu-
tation adjusted p-values after 1,000,000 permutations have been calculated using PLINK. Because we excluded 
all the variants with a frequency below 1% we also wanted to test if there was a significant association between 
pneumococcal meningitis patients and healthy controls with the inclusion of these rare variants. To test this we 
applied the gene-based test Sequence Kernel Association Test (SKAT) adaptive sum to test the association of the 
phenotype and SNP sets per gene with all variations having the same weight22,37. Secondly we tested all genes with 
the combined test of rare and common variants to look at the effect of rare variants22,37. For the gene-based SKAT 
test we corrected for any population stratification by including the first four MDS dimensions. To determine the 
proportion of case-control imbalance we used implemented hybrid-resampling method built in SKAT22,37.
Ethics statement. The MeninGene study was approved by the ethics committee of the Academic Medical 
Center, Amsterdam, The Netherlands. Ethical approval was granted in all participating centers and written 
informed consent was obtained from all participating individuals or legally authorized representatives. The study 
was conducted according to the principles of the Declaration of Helsinki (version of 2013, Fortaleza, Brazil) and 
in accordance with the Medical Research Involving Human Subjects Act (WMO) and other guidelines, regula-
tions and acts. The UHP study was approved by the Medical Ethical Committee of the University Medical Center, 
Utrecht, The Netherlands and written informed consent was obtained from all participants.
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